Litcius/Paper detail

The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: Lessons being learned and new questions emerging from phase 3 trial long-term outcome data

Ursula A. Matulonis

2022Gynecologic Oncology10 citationsDOI

Topics & Concepts

MedicinePARP inhibitorOncologyPlaceboInternal medicineOvarian cancerClinical trialCancerIntensive care medicinePoly ADP ribose polymerasePolymeraseAlternative medicinePathologyGeneChemistryBiochemistryPARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentAdvancements in Semiconductor Devices and Circuit Design
The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: Lessons being learned and new questions emerging from phase 3 trial long-term outcome data | Litcius